Stock Performance and Market Context
The stock of Gujarat Kidney & Super Speciality Ltd, a micro-cap entity in the hospital industry, demonstrated a strong upward trajectory on 01 September 2026, closing at Rs 164.00, which represents its highest-ever closing price. This peak was accompanied by an intraday high of Rs 162.6, reflecting a 2.49% gain during the trading session. The stock outperformed its sector by 2.77% and the broader Sensex index by a substantial margin, with a day change of 3.37% compared to Sensex’s 0.35% rise.
Over various time frames, the stock has exhibited remarkable strength. Its one-week gain stands at 7.68%, contrasting with the Sensex’s decline of 0.55%. The one-month performance is particularly impressive, with a 28.78% increase against the Sensex’s 1.11% fall. Over three months, the stock rose 21.17%, significantly outpacing the Sensex’s 3.99% gain. Year-to-date, Gujarat Kidney & Super Speciality Ltd surged 59.61%, while the Sensex declined by 9.38%. These figures underscore the stock’s resilience and strong momentum within a challenging market environment.
Technical Indicators and Trend Analysis
The technical outlook for Gujarat Kidney & Super Speciality Ltd remains mildly bullish. The stock is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained upward momentum. The current trend was confirmed on 24 August 2026 when the stock crossed ₹152.6, shifting from a bullish to a mildly bullish stance.
Key technical indicators present a mixed but generally positive picture. The MACD and Dow Theory indicators are bullish on both weekly and monthly timeframes, while Bollinger Bands suggest a mildly bullish trend. The RSI indicator shows bearish tendencies, indicating some caution in momentum strength. Immediate support is established at the 52-week low of ₹98.25, with resistance levels at ₹145.41 (20 DMA) and ₹131.40 (100 DMA). The stock’s current price at ₹164.00 represents a new resistance level as it reaches its 52-week high.
Valuation Metrics and Financial Quality
At the current price, Gujarat Kidney & Super Speciality Ltd trades at a price-to-earnings (P/E) ratio of 79x on a trailing twelve months (TTM) basis, reflecting a premium valuation consistent with its growth profile. The price-to-book value stands at 4.95x, while enterprise value multiples include EV/EBITDA at 45.42x and EV/EBIT at 55.02x. The EV/Sales ratio is 14.92x, and EV/Capital Employed is 5.43x. Dividend metrics are not applicable as the company has not declared dividends recently.
The company’s quality assessment highlights several strengths. It maintains an excellent capital structure with low leverage, evidenced by an average debt to EBITDA ratio of 0.92 and net debt to equity at zero. The average return on capital employed (ROCE) is a robust 26.45%, indicating efficient use of capital. Management risk is assessed as average, while growth is rated excellent. The company has no promoter share pledging and holds a low institutional ownership of 5.44%.
Financial Trends and Recent Performance
Recent financial trends show positive momentum. Net sales for the nine months ending June 2026 rose to ₹88.12 crores, with profit after tax (PAT) increasing to ₹13.16 crores. The profit before tax excluding other income for the latest quarter was ₹6.27 crores, reflecting a growth rate of 23.1% compared to the previous four-quarter average. These figures demonstrate the company’s ability to sustain growth and profitability in its core operations.
Delivery volumes have surged notably, with a 1-day delivery change of 255.28% compared to the 5-day average and a 1-month delivery increase of 143.32%. On 31 August 2026, delivery volume reached 8.84 lakh shares, accounting for 43.40% of total volume, indicating heightened trading activity and investor engagement.
Historical Performance Comparison
While the stock’s one-year, three-year, five-year, and ten-year returns are recorded as zero, this is likely due to data limitations or recent listing status. However, the Sensex benchmark shows significant gains over these periods, with a 10-year return of 171.70%. The stock’s recent surge and all-time high price suggest a phase of accelerated growth and market recognition.
Market Capitalisation and Rating Update
Gujarat Kidney & Super Speciality Ltd is classified as a micro-cap company. Its Mojo Score currently stands at 62.0, with a Mojo Grade of Hold, reflecting a recent downgrade from Buy on 24 August 2026. This adjustment aligns with the evolving market conditions and valuation considerations.
Summary
The attainment of an all-time high stock price of Rs 164 by Gujarat Kidney & Super Speciality Ltd marks a significant milestone in its market journey. Supported by strong financial results, positive technical indicators, and robust delivery volumes, the stock has demonstrated resilience and outperformance relative to its sector and the broader market. While valuation multiples suggest a premium, the company’s quality metrics and recent growth trends provide a solid foundation for this achievement.
